Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of subcutaneous reslizumab 110 mg in severe eosinophilic asthma
2016-004661-23Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reslizumab in asthma and eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Frequency of adverse events including serious adverse events. Started Feb 2017; status: completed.
02
Drugs
reslizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2016-004661-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004661-23.